These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

212 related articles for article (PubMed ID: 18398734)

  • 1. Novel anti-myeloma agents and angiogenesis.
    Anargyrou K; Dimopoulos MA; Sezer O; Terpos E
    Leuk Lymphoma; 2008 Apr; 49(4):677-89. PubMed ID: 18398734
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Novel therapies targeting the myeloma cell and its bone marrow microenvironment.
    Hideshima T; Chauhan D; Podar K; Schlossman RL; Richardson P; Anderson KC
    Semin Oncol; 2001 Dec; 28(6):607-12. PubMed ID: 11740818
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Patients with multiple myeloma treated with thalidomide: evaluation of clinical parameters, cytokines,angiogenic markers, mast cells and marrow CD57+ cytotoxic T cells as predictors of outcome.
    Mileshkin L; Honemann D; Gambell P; Trivett M; Hayakawa Y; Smyth M; Beshay V; Ritchie D; Simmons P; Milner AD; Zeldis JB; Prince HM
    Haematologica; 2007 Aug; 92(8):1075-82. PubMed ID: 17640854
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Thalidomide and lenalidomide in the treatment of multiple myeloma.
    Kumar S; Rajkumar SV
    Eur J Cancer; 2006 Jul; 42(11):1612-22. PubMed ID: 16750621
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [The plasma cell myeloma--molecular pathogenesis and target therapies].
    Hess U
    Ther Umsch; 2006 Apr; 63(4):233-6. PubMed ID: 16689452
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A review of angiogenesis and antiangiogenic therapy with thalidomide in multiple myeloma.
    Rajkumar SV; Witzig TE
    Cancer Treat Rev; 2000 Oct; 26(5):351-62. PubMed ID: 11006136
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Bone marrow angiogenesis and angiogenic factors in multiple myeloma treated with novel agents.
    Cibeira MT; Rozman M; Segarra M; Lozano E; Rosiñol L; Cid MC; Filella X; Bladé J
    Cytokine; 2008 Mar; 41(3):244-53. PubMed ID: 18178097
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Current treatment landscape for relapsed and/or refractory multiple myeloma.
    Dimopoulos MA; Richardson PG; Moreau P; Anderson KC
    Nat Rev Clin Oncol; 2015 Jan; 12(1):42-54. PubMed ID: 25421279
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Novel biologically based therapies for myeloma.
    Anderson KC
    Cancer J; 2001; 7 Suppl 1():S19-23. PubMed ID: 11504280
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Contemporary drug therapies for multiple myeloma.
    de la Puente P; Azab AK
    Drugs Today (Barc); 2013 Sep; 49(9):563-73. PubMed ID: 24086952
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Carfilzomib and pomalidomide: recent advances in the treatment of multiple myeloma.
    Highsmith KN; Chen SE; Horowitz S
    Pharmacotherapy; 2014 Sep; 34(9):927-40. PubMed ID: 25044413
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Therapeutic use of immunomodulatory drugs in the treatment of multiple myeloma.
    Raje N; Hideshima T; Anderson KC
    Expert Rev Anticancer Ther; 2006 Sep; 6(9):1239-47. PubMed ID: 17020458
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Lenalidomide in multiple myeloma.
    Richardson PG; Mitsiades C; Hideshima T; Anderson KC
    Expert Rev Anticancer Ther; 2006 Aug; 6(8):1165-73. PubMed ID: 16925483
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Proteasome inhibitors and modulators of angiogenesis in multiple myeloma.
    Ferrarini M; Ferrero E
    Curr Med Chem; 2011; 18(34):5185-95. PubMed ID: 22087819
    [TBL] [Abstract][Full Text] [Related]  

  • 15. New drugs for myeloma.
    Richardson PG; Mitsiades C; Schlossman R; Munshi N; Anderson K
    Oncologist; 2007 Jun; 12(6):664-89. PubMed ID: 17602058
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Tumor angiogenesis in the bone marrow of multiple myeloma patients and its alteration by thalidomide treatment.
    Du W; Hattori Y; Hashiguchi A; Kondoh K; Hozumi N; Ikeda Y; Sakamoto M; Hata J; Yamada T
    Pathol Int; 2004 May; 54(5):285-94. PubMed ID: 15086832
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Molecular mechanisms of effectiveness of novel therapies in multiple myeloma.
    Bianchi G; Ghobrial IM
    Leuk Lymphoma; 2013 Feb; 54(2):229-41. PubMed ID: 22897729
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Novel therapeutic avenues in myeloma: changing the treatment paradigm.
    Ghobrial J; Ghobrial IM; Mitsiades C; Leleu X; Hatjiharissi E; Moreau AS; Roccaro A; Schlossman R; Hideshima T; Anderson KC; Richardson P
    Oncology (Williston Park); 2007 Jun; 21(7):785-92; discussion 798-800. PubMed ID: 17722741
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Bortezomib: a valuable new antineoplastic strategy in multiple myeloma.
    Bladé J; Cibeira MT; Rosiñol L
    Acta Oncol; 2005; 44(5):440-8. PubMed ID: 16118077
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Outcomes of multiple myeloma patients receiving bortezomib, lenalidomide, and carfilzomib.
    Berenson A; Vardanyan S; David M; Wang J; Harutyunyan NM; Gottlieb J; Halleluyan R; Spektor TM; Udd KA; Eshaghian S; Nassir Y; Eades B; Swift R; Berenson JR
    Ann Hematol; 2017 Mar; 96(3):449-459. PubMed ID: 27933373
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.